{"denoms":[{"counts":[{"groupId":"BG000","value":"331"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"331"},{"groupId":"BG003","value":"331"},{"groupId":"BG004","value":"1065"}],"units":"Participants"}],"groups":[{"description":"Placebo subcutaneous injection (given under the skin by way of a needle) matched to golimumab administered at Week 0 and Week 2.","id":"BG000","title":"Placebo"},{"description":"Golimumab 100 milligram (mg) subcutaneous injection was administered at Week 0 and dose was decreased to 50 mg at Week 2.","id":"BG001","title":"Golimumab 100 mg -> 50 mg"},{"description":"Golimumab 200 mg subcutaneous injection was administered at Week 0 and dose was decreased to 100 mg at Week 2.","id":"BG002","title":"Golimumab 200 mg -> 100 mg"},{"description":"Golimumab 400 mg subcutaneous injection was administered at Week 0 and dose was decreased to 200 mg at Week 2.","id":"BG003","title":"Golimumab 400 mg -> 200 mg"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.04","value":"39"},{"groupId":"BG001","spread":"12.19","value":"40.9"},{"groupId":"BG002","spread":"13.54","value":"40"},{"groupId":"BG003","spread":"13.75","value":"40.7"},{"groupId":"BG004","spread":"13.37","value":"40"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"151"},{"groupId":"BG003","value":"130"},{"groupId":"BG004","value":"469"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"180"},{"groupId":"BG003","value":"201"},{"groupId":"BG004","value":"596"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}